RALA and familial pancreatic carcinoma: Finally, we showed the specific protein alterations related to the different malignant ascites bearing tumors development, such as TSP1 and CDK4 for bladder cancer, RALA and RALB for pancreatic cancer, GSTM6 and HMOX1 for hepatocellular cancer, etc. In addition, the protein expressions of various tumors caused by chemical carcinogenesis, viral carcinogenesis also changed in the MS275 treatment group.